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Abstract
Background: Randomized controlled trials (“randomized trials”) can provide evidence to assess the equity impact of
an intervention. Decision makers need to know about equity impacts of healthcare interventions so that people get
healthcare that is best for them. To better understand the equity impacts of healthcare interventions, a range of
people who were potentially the ultimate users of research results were involved in a six-phase project to extend
the CONsolidated Standards Of Reporting Trials Statement for health equity (“CONSORT-Equity 2017”). We identified
these “knowledge users” as: patients and healthcare researchers, decision makers and providers. This paper reports
on one project phase: specifically, a qualitative study designed to integrate the expertise of knowledge users. The
experiences and perspectives of knowledge users provided many insights about the reporting of health equity
issues in randomized trials. This paper describes key informant interviews with knowledge users that contribute to a
better understanding of the effects of an intervention on health equity. Additionally, the paper shows how these
insights were used to develop CONSORT-Equity 2017.
Methods: A qualitative study that used the framework analysis method was conducted in collaboration with an
international study executive and advisory board team. In-depth semi-structured interviews were conducted with a
purposive sample of key informants who: consider the research ethics of, fund, conduct, participate in, publish, or
use research evidence generated in randomized trials. Transcripts were coded and analyzed using the seven-stage
framework analysis method, and data reported to reflect knowledge user suggestions to develop CONSORT-Equity
2017.
Results: Thirteen key informants, of which three were patients, chose to participate in interviews. Seven themes
emerged: “Differentiate the type of trial”, “Prompts for health equity”, “Ethics matter”, “Describe unique research
strategies”, “Clarity of reporting”, “Implications of equity for sampling and analysis”, “Think beyond the immediate
trial”. The interviews provided direction for the extension of 16 CONSORT-Equity 2017 items.
Conclusions: Key informant interviews were used to identify new concepts that were not generated in our other
studies and to develop CONSORT-Equity 2017. We encourage the use of key informant interviews in guideline
development to obtain and include the real-life expertise of knowledge users.
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Plain Language Summary
Healthcare decision makers need to know the pros and
cons of treatments to address health issues. Health
equity is about ways to know about and address unfair
differences in health for groups of people. To promote
health equity, decision makers need to know if the pros
and cons of treatments might differ across groups of
people, so that more people can get the healthcare best
for them. For this reason a guideline to report research
details about health equity was made.
In a study to make the guideline to report research
details about health equity, we talked with a range of
people who join in or use healthcare research and that
include patients, healthcare researchers, healthcare deci-
sion makers and healthcare providers. Our research
shows that all of these “knowledge users” have expertise
to share and that their ideas should be valued. We also
wanted to know what knowledge users think are key re-
search details about health equity. We describe talking
with a group of 13 knowledge users of which 3 were
patients, about what they view as key ways to report
research details about health equity. Then, we describe
how what was learned in talking with knowledge users
was used to make the guideline. We conclude that talk-
ing with knowledge users is a way to improve guidelines
that report on key research details about health equity
so that more people can get the healthcare that is the
best for them.
Background
Evidence-based decision making aims to integrate
research evidence with practical knowledge for use by
health decision makers, and this can have important im-
plications for healthcare systems and consumers [1]. The
promotion and utilization of research findings, in both
healthcare and health policy, is a tenet of international
policies on research for health [2–4]. Considerable efforts
have been made to understand and reduce the key sources
of bias in research in order to contribute the best evidence
for use in health systems. Randomized controlled trials
(“randomized trials”), for example, minimize the risk of
bias and are more likely to result in moderate or high cer-
tainty evidence than non-randomized studies [5]. Ran-
domized trials can provide evidence on both the desirable
and undesirable effects of interventions, as well as the dif-
ferential effects across subpopulations. Differences in
health within or between population groups within soci-
ety, or health inequalities, are labeled “inequities” when
they are considered unfair [6]; that is, when they are
potentially avoidable [7]. There is a need to study and re-
port on differences in the effects of interventions for
population groups to assist those who make decisions in
health systems to improve health equity and to ensure that
healthcare consumers receive the best care.
Randomised trials can provide evidence relevant to
assessing the equity impact of an intervention. A ran-
domized trial can be classified as “health equity relevant”
if it assesses the effects of an intervention on health or
on the determinants of health for a population who ex-
perience ill-health due to disadvantage defined across
one or more factors (“social determinants of health”) [8].
A randomized trial is also health equity relevant if it
compares the effectiveness of the intervention across
levels of advantage/disadvantage. We defined two types
of randomized trials relevant to health equity: 1) ran-
domized trials focused on a population experiencing a
disadvantage (e.g. low-income parents), and 2) universal
randomized trials where differential effects are assessed
(e.g. analysis of effects of programs for low-income vs
higher income parents) [8]. Reported evidence from
randomized trials on health equity can be incorporated
into systematic reviews and review-derived products (pol-
icy briefs, overviews, guidance documents) to contribute
to a robust evidence base for decision making that con-
siders impacts on health equity across populations.
The CONsolidated Standards Of Reporting Trials
Statement (“CONSORT Statement”) comprises an
evidence-based set of recommendations for reporting
randomized trials. The CONSORT Statement consists of
a 25-item checklist and flow diagram. The checklist
focuses on reporting how the trial was designed, ana-
lyzed and interpreted, whereas the flow diagram depicts
participant progress through the trial processes. Exten-
sions to the CONSORT Statement have been developed
for specific issues, such as reporting of cluster random-
ized trials, harms, pragmatic trials, non-pharmacologic
therapies, and social and psychological interventions [9].
As none of the existing extensions of the CONSORT
Statement cover the items for reporting needed to assess
the effects of an intervention on health equity [10], a
program of research was undertaken to develop an
extension of the CONSORT Statement to improve
reporting of health equity relevant randomized trials
[11]. In the development of the program of research, it
was identified that there is a need for more active roles
of patients and public as part of a group of potential
“knowledge users”: individuals directly affected by
research and inclusive of those who occupy a range of
positions in health systems [12]. The participation of
knowledge users in the conceptual development of
reporting guidelines, their contributions to an evidence
base for patient involvement and their confirmation that
what is being reported is of relevance to patients and the
public were all identified as important in the work to
extend the CONSORT Statement for equity. For this
reason, it was defined as critical that the work be done
in a way that is inclusive of people for whom the re-
search is meant to ultimately be of use. In other words,
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to also include those who are, have been or who may be-
come research participants/community collaborators
and/or who are knowledge users of the evidence from
randomized trials. This paper reports on one study con-
ducted as part of a program of research that aims to
integrate knowledge user involvement in the conceptual
development of a reporting guideline (Fig. 1).
The extension of the CONSORT Statement for equity
(“CONSORT-Equity 2017”) [11] followed the proposed
steps for developing consensus-based reporting guidelines
described by Moher et al. [13]. Because ensuring the up-
take of CONSORT-Equity 2017 is critical to influence
reporting of future randomized trials, the decision was
made to use an integrated knowledge translation approach
which engages knowledge users as partners throughout the
process. The aim was to foster thinking about, and inclu-
sion of, a multiplicity of perspectives [11, 14]. A key feature
in the development of CONSORT-Equity 2017 has been
the involvement of an international and inter-disciplinary
study executive (a small group of people who take respon-
sibility for developing and executing the project) and an
advisory board [10].
The study executive members represent a range of disci-
plines including clinical epidemiology, social science, public
health, and international development. Study executive
members were consulted regularly through planned meet-
ings. Members of the study executive identified the import-
ance of collaboration with knowledge user groups during
the development of CONSORT-Equity 2017. We also
recruited an international advisory board, being careful to
include a broad range of member perspectives, including:
patients, journal editors, trialists, bioethicists, clinicians,
systematic review authors, policy makers, and funders.
These knowledge users are described in greater detail else-
where [10]. The role of the advisory board membership
was agreed upon by study executive and advisory board
members: specifically, the advisory board was to participate
in a collaborative process, provide content-related support,
and bring knowledge, skills and experience to the working
group throughout the multiple stages of the research
process. The advisory board was facilitated by one re-
searcher (JJ) to ensure communication within and between
the advisory board and study executive groups. As well, the
inclusion of the advisory board created an opportunity for
debate and discussion among the study members, such as
the exploration and expansion of concepts related to health
equity [8, 10]. Their contributions throughout the steps of
the program of research guided the development of
CONSORT-Equity 2017.
To ensure knowledge user participation, the study
executive and advisory board members decided to adapt
the guidelines described by Moher et al, to include inter-
views with knowledge users as “key informants”; that is,
individuals who are potentially the ultimate users of the
results of the research. It was important to engage with
those who consider the ethics of, fund, conduct, partici-
pate in, publish or use the research evidence generated
in randomized trials who have a range of perspectives
Fig. 1 Research Program for CONSORT Equity
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and expertise that would be difficult to capture through
an online survey alone. As well, it was important to pro-
mote an approach to guideline development that creates
opportunities for the inclusion of knowledge users,
including patients and the expertise that these groups
offer. Differences in culture, training, priorities et cetera
create challenges to practicing partnered research that
leads to co-creation of knowledge, and we describe our
approach to engagement with knowledge users in guide-
line development. The purpose of interviews with key
informants was to elicit detailed knowledge user views
on the ways to improve reporting of intervention effects
related to health equity in randomized trials. The aim of
this manuscript is twofold: (i) to describe key informant
views about items for reporting to assess effects of an
intervention on health equity, and (ii) to describe how
the key informant interviews were used to develop
CONSORT-Equity 2017.
Methods
The details of this study and the development of
CONSORT-Equity 2017 are described elsewhere [10, 11].
Key informant interviews are an efficient way to engage
with, collect and synthesize an array of views. The Bruyère
Research Institute’s Research Ethics Board approved this
study in February 2016 (Protocol # M16-15-042). Funded
by Canadian Institutes of Health Research (MOP_133556).
Design
This was a qualitative study using in-depth, semi-structured
interviews. Health equity issues span a broad range of
disciplinary fields that may have different approaches to
reporting randomized trials. We aimed to achieve
inter-disciplinary relevance of CONSORT-Equity 2017 as a
reporting guideline. Therefore, we sought knowledge user
views about how to improve reporting of equity-relevant
randomized trials in a way that aligned with the
multi-disciplinary, theoretical and ethical approach used in
the CONSORT-Equity 2017 study and reported in Table 1
[15]. Key informant interviews were identified as a
method acceptable to potential participants and to
CONSORT-Equity 2017 team members. The use of
key informant interviews created opportunities to
engage with participants and obtain potentially new
knowledge in the guideline development process. The
participant sample size was determined by theoretical
saturation, defined as when subsequent interviews
contribute no new concepts. We estimated that this
would occur at 10–13 interviews [16]. Qualitative key
informant interviews were conducted from March
2016 to July 2016 so that results could feed into the
later phases of the guideline development process.
We then analysed the qualitative data with the frame-
work method of thematic analysis [17]. The frame-
work method involves development of an analytical
framework that is then used to organize and index
data, and, if needed, to make adjustments to the
framework for any additional themes [17]. The study
was conducted with iterative feedback from the study
executive and advisory board members.
Setting and participants
We used a purposive sampling approach [18] and identi-
fied potential participants for key informant interviews
through contacts suggested by the study executive and
advisory board members. In order to ensure that partici-
pants were from knowledge user groups, we included
people who are involved in the ethical approval, funding,
conduct, publication, or use of research evidence gener-
ated in randomized trials, or who participate in random-
ized trials. Participants were selected to maximize
variation of disciplines and experience (for example,
their role in relation to health research, years of experi-
ence in the role, familiarity with CONSORT Statement,
general region of current work) and with a focus on
those who are known to be direct users of CONSORT
Statement as a reporting guideline. We faced challenges
in identifying knowledge users who are patients and had
experience with participation in randomized trials and
who might be interested in our study, which was in itself
Table 1 GRIPP (Guidance for Reporting Involvement of Patients and the Public) 2 Short Form Reporting checklist for study conduct
Section and Topic Item Reported on page No.
1. Aim Report the aim of PPIa in the study Aim described in Abstracts (see lay and technical),
and Background section (para. 4 and 5)
2. Methods Provide a clear description of the methods used for PPI in the study Methods section see “Design” and “Setting and
participants” section (para. 2,3 in methods)
3. Study results Outcomes – report the results of PPI in the study, including both
positive and negative outcomes
See “Results” section, “Limitations and Strengths”
paragraphs that discuss PPI
4. Discussion and
conclusions
Outcomes – Comment on the extent to which PPI influenced the study
overall. Describe positive and negative effects
See “Discussion” (para. 2,4) and “Limitations and
Strengths” section
5. Reflections/critical
perspective
Comment critically on the study, reflecting on the things that went well,
and those that did not so others can learn from this experience
See “Limitations and Strengths” section
aPatient and public involvement
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an important observation of the study. Interviews were
conducted either in person or with the use of video con-
ference software and were digitally audio-recorded and
with notes taken by the researcher during the interviews.
The names and identifying characteristics of the study
participants were not reported to preserve anonymity.
Procedure
All interviews were conducted by the first author (JJ)
who is experienced in qualitative research and who has
played a leadership role in other qualitative studies that
involve engagement with a range of knowledge user par-
ticipants [19, 20]. The lead researcher (JJ) has been in-
volved with the development of CONSORT-Equity 2017:
this involvement has been focused on the engagement of
knowledge users in the study as the lead of the advisory
board and integration of knowledge user views in the
CONSORT-Equity 2017 [11]. A semi-structured inter-
view guide based on a previous study conducted with
patient participants [19] was developed with feedback
from the study executive and advisory board members
and pilot-tested. The interview guide was designed to
invite feedback on the original CONSORT Statement
items as well as to seek new candidate items for inclu-
sion in the proposed version of CONSORT-Equity 2017
(Table 2). Information that introduced study concepts
and the aims of the CONSORT-Equity 2017 study was
developed and pilot-tested with a range of knowledge
user groups and that included patients and members of
the public. Written informed consent was sought and
obtained from all participants. First, participants were
oriented to the study concepts, that is, there was an
explanation for the rationale and processes used to
develop CONSORT-Equity 2017 as well as how the key
informant interviews were anticipated to contribute to
the overall study process. Then, participants were pro-
vided with a working definition of “health equity” and
with examples. Other concepts related to the CONSORT
Statement and our work to define health equity relevant
randomized trials were clarified [5, 7]. Next, participants
were led through a 30 to 60 minute interview with the
25-item CONSORT Statement and asked about the
CONSORT Statement in relation to reporting health
equity considerations. They were also asked to explain
their views. Interviews were conducted with participants
until we reached saturation of key concepts [16]. We
also conducted three additional interviews to confirm that
new concepts did not emerge. The digital audio-recorded
interviews were transcribed verbatim, anonymized, and
then reviewed by the researcher (JJ) and returned to each
key informant participant for member checking so that
participants could confirm their transcript for accuracy.
Data analysis
The framework method is a systematic approach to
qualitative content analysis of data that identifies similar-
ities and differences, defines relationships, and builds
conclusions. In our study, the framework method was
selected for analysis of the qualitative interviews as a
useful way to explore and link information gathered
from an array of interview participants. The framework
method was also selected because it is a pragmatic
Table 2 Questions asked during key informant interviews
Topic Question Probes
Experience Q1. Do you have any experience with reading/using/doing/
participating in trials you might consider equity-relevant?
Prompt: Some experience? None? Interest in? Value
of? Can you explain your role? When was this?]
Familiarity with checklist use Q2. Would you explain your experience with CONSORT? Prompt: Some experience? None? Interest in? Value
of? Can you explain your role? When was this?
Feedback on the checklist.
[Make sure that the participant
has a copy of the checklist in
front of them]
Q3. a. Now I will review each section of the CONSORT
checklist with you and will ask you about it, okay? For the
section titled [title/abstract et cetera – each section of the
checklist], is it important that the information on how equity
is relevant for the trial is reported for the [title/abstract et
cetera]?
[This process will be repeated with each section of CONSORT
checklist – there are six sections: title/abstract, introduction,
methods, results, discussion, other information. There are
subsections for each section and it is expected that
participants will refer to subsections and issues of particular
importance, if needed].
Why?
Are there any reasons that it might be challenging
to include information on how equity is relevant for
a trial in this section?
[For each section of the CONSORT checklist]
Perceived use of checklist Q4. Would you use the CONSORT checklist if it was modified
to include equity-relevant considerations?
Why or why not?
Perceived relevance of
checklist
Q5. Would you encourage others to use the CONSORT
checklist if it was modified to include equity-relevant
considerations?
Why or why not?
Additional comments Q6. Any other comments or suggestions to make the
checklist better for reporting equity-relevant trials?
-
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approach: it is useful when multiple researchers in
multi-disciplinary teams are working together [17]. The
pragmatic feature of the framework method was viewed
as an important factor in our research, which included
study executive and advisory board members who might
not have been familiar with qualitative methods. The
framework approach requires leadership from an experi-
enced qualitative researcher, and allows involvement of
non-specialists in the analysis process [17]. The tran-
scripts of interviews underwent analysis by two inde-
pendent reviewers (JJ, MY). JJ led the analysis with the
second reviewer (MY) independently confirming the
analysis process: all disagreements were reviewed by a
third investigator (VW). The seven-stage process of the
framework method was used for analysis [17]. These
stages were: 1) transcription; 2) familiarization with the
interview by reviewers; 3) the generation of initial codes
within each transcript interpreted by reviewers as im-
portant (e.g. “different types of equity studies”; “don’t
make assumptions”; 4) development of a working analyt-
ical framework after coding the first few transcripts, and
comparison of the labels among the reviewers (JJ, MY)
to agree on the set of codes to use in the subsequent
transcripts (e.g. “differentiate the type of trial”; “prompts
for equity”); 5) application of the analytical framework;
6) inserting data from the remaining transcripts into the
framework (further confirmed or adjusted by the second
reviewer (MY) to ensure consistency); and 7) interpret-
ation of data so that the characteristics of and differ-
ences between the data were identified. The data were
reported so that the participant rationales for the com-
ments and/or suggestions for change extend the CON-
SORT Statement for equity. Two people (JJ, MY) were
central to the process and others, directly involved study
executive members (EK, JP, MP, PT, VW), had the
process described to them, with opportunities for feed-
back from members of the study executive and advisory
board. At the completion of the analysis, findings were
reviewed and confirmed with study executive members.
Following analysis, the themes generated during the
key informant interviews were used in the development
of CONSORT-Equity 2017, and the information used in
the subsequent phases (to collect broad feedback and
prioritize items needed to improve reporting of health
equity in randomized trials, establish consensus on
CONSORT-Equity 2017) to develop CONSORT-Equity
2017 [11].
Results
Participant characteristics
We interviewed 13 people of which three were patients
active in research and so identified as “participant/re-
search collaborator” (Table 3). During the initial recruit-
ment, three potential interviewees declined and all three
indicated this was due to lack of time to participate in
the interview process. Participants self-identified as hav-
ing one or more roles in research, with many identifying
as having more than one role (for example, “participant/
research collaborator” and “researcher” , “researcher”
and “journal editor”). Participants reported a mix of re-
search involvement (meaning in the funding, develop-
ment of, conduct, participation in, dissemination of, or
use of outcomes from randomized trials). They also re-
ported a range of experiences with the use of different
types of study designs (quantitative, including random-
ized trials; qualitative; mixed methods; and, systematic
reviews). Most participants reported having used or re-
ferred to the CONSORT Statement. Participants identi-
fied their primary regions of work related to health
equity as based in their country of residence and/or
internationally.
Participant reflections on a need for the equity extension
for CONSORT
The participants were interested in exploring the poten-
tial for the extension of the CONSORT Statement to
Table 3 Background characteristics of participants (n=13)a
Characteristics Frequency
Role in health research
Funder 1
Ethicist 1
Researcher (includes clinician-researchers) 8
Participant/research collaborator 3
Publisher/journal editor 2
Policy/decision maker 2
Years of experience in role
1-5 years 2
5-10 years 4
More than 10 years 7
Type of research design
Quantitative 2
Qualitative 3
Mixed Methods 2
Systematic Reviews 3
All 4
Have used (reported or refer to) CONSORT reporting guidelines
Yes 9
No 4
Region of current work
Country of residence 6
International 7
aParticipants could identify as belonging to more than one category of
knowledge user
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accommodate consideration of health equity in the
reporting of randomized trials. Participant responses
to questions were classified into seven themes: “Dif-
ferentiate the type of trial”, “Prompts for health
equity”, “Ethics matter”, “Describe unique research strat-
egies”, “Clarity of reporting”, “Implications of equity for
sampling and analysis”, “Think beyond the immediate
trial”. The value added by key informant interviews to the
extension of the CONSORT Statement for equity is re-
ported in Table 4.
“Differentiate the type of trial”
Most participants emphasized the need to be able to re-
port differently about a focused randomized trial with an
explicit and sole focus on assessing intervention
effectiveness in a population that experiences a disad-
vantage (e.g. low income parents) that is linked to poor
health in relation to the general population (i.e. leads to
health inequity). This is compared to a universal
randomized trial in which a sub-analysis has been
conducted to assess differential effects between popu-
lations (e.g. between low-income children and chil-
dren from families of higher socioeconomic status).
Participants felt that the CONSORT Statement would
need to be adjusted to account for these different
types of randomized trials to report on equity-related
information:
“[how equity is reported depends upon] if equity is
at the heart of what you’re doing either because you’re
focusing on a specific subgroup or you’re working in a
low and middle income country then….then I don’t
know exactly how to say this - but I think the point is
that it just depends a bit on how equity fits within
your overall narrative” (Interview #5: researcher, pub-
lisher/editor).
Table 4 Value added to the overall development of CONSORT Equity
Category 1: “Differentiate the type of trial”
This category contributed to thinking and discussion during the Delphi and consensus meeting about the extension of CONSORT Statement items to
report if equity is a major focus in the title (Item 1a) and in the abstract section to consider reporting any research question(s) related to health equity, as
well as the results of all planned health equity analyses and the extent and limits of applicability across population characteristics (Items 1b).
Category 2: “Prompts for health equity”
This category contributed to thinking and discussion about how to extend the CONSORT Statement background section so that reporting on the
rationale to focus on health equity could be explicit, and also provided the opportunity to state whether or how the objectives of the trial relate to
health equity (Items 2a, 2b).
For this reason, in the survey and discussions that followed the key informant interviews, concerns about whether and how to extend the CONSORT
Statement for equity were considered so that they would be most likely “usable”. Findings helped to guide the broad inclusion of membership in
the Delphi survey and invitations to attend the face-to-face consensus meeting. Care was taken to define health equity in trials and examples of
“health-equity relevant trials” sought and tested and agreed upon by the CONSORT Equity core team and advisory board.
Category 3: “Ethics matter”
As there are no items related to ethics in the original CONSORT Statement, participant suggestions led to the proposal in the Delphi survey for the
addition of a new item (to report details of ethical concern and patient/community engagement) and consideration for extensions of existing items
to bring equity considerations forward within the randomized trials (for example, item 6a to report whether items were identified as relevant and
important to populations and how it was done). These extension items were affirmed during the Delphi study and then further discussed (and
approved) during the consensus meeting.
Category 4: “Opportunity to describe unique research strategies”
During the interviews, most key informants raised concerns about innovative approaches to research that facilitate inclusive randomized trials. For this
reason, the extension of the item about randomized trial design to describe aspects of the study design that were chosen to answer equity questions was
specifically proposed and then voted upon in the Delphi study. The inclusion of an item to describe unique research strategies was then discussed during
the consensus meeting and agreed upon with changes made to ensure there were opportunities to describe/explain unique strategies with description of
trial design (item #3a).
Category 5: “Details are important”
This category contributed to thinking and discussion during the Delphi and consensus meeting about the extension of CONSORT Statement items to
consider reporting on research methods and the reporting of details on participants and the settings and locations where the data were collected
(items 4a, 4b). As well, this contributed to the background information for CONSORT Equity and the explicit use of the PROGRESS Plus framework to
guide the thinking about how to describe details on the study as they relate to health equity (item 15).
Category 6: “Guidance for statistics”
Many participants emphasized the benefits of consultation with a biostatistician to help with general barriers to sample size calculations and the lack
of evidence about equity-relevant trials and statistical analysis. For this reason, care was taken to include biostatisticians in the Delphi survey and as
part of the group membership at the consensus meeting. During the Delphi survey and the consensus meeting there was broad discussion about
sample size and the importance of reporting and that focused to be about whether analyses are powered to detect differences (item 7a) as well as
about any additional analyses focused on health equity (item 12b) and ancillary analysis (item 18).
Category 7: “Think beyond the immediate trial”
During the Delphi study additional detail for items about harms and the study discussion section were proposed. These were carried forward to the
consensus meeting and discussion focused on the need for reporting about whether intervention generated inequities (that is, unintended effects)
were assessed, any limitations related to assessing effects on health equity, and reporting of applicability related to the population of interest (Items
19, 20, 21). For, as one participant stated “identifying inequity is the first step but it does not get us further in promoting equitable health if we don’t
move past and say “now what?””.
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“I have heard of trials…that have conceptualized equity
as a sort of first - like a primary outcome – that has been
made explicit and in that case you’d definitely want that
[focus on reporting health equity with the CONSORT
Statement checklist]. But I think that if you are talking
about some sort of secondary analysis maybe less so”
(Interview #7: researcher).
“Prompts for health equity”
Participants indicated the need to report the features of
randomized trials that relate to health equity, and to en-
hance the CONSORT Statement users’ understandings
of equity. All participants discussed the importance of
description about how the randomized trial relates to
health equity. The re-structuring of the CONSORT
Statement so that it is possible to reflect the type of con-
tributions a randomized trial has made to evidence
about health equity was identified as important:
“So they [researchers using the reporting guideline]
would really have to define what they [researchers] mean
by inequities, how they’re measuring it, and what thresh-
old they’re going to use to say equity has been improved
or inequity reduced. Yeah – so that might be challenging
because this is a really new, a new field” (Interview #9:
researcher).
Most participants emphasized the need for knowledge
user education to prompt critical thinking about health
equity (for instance about what is meant by “health
equity relevant”, how to identify information related to
health equity):
“People need to be educated on where equity can be
found so if they are doing systematic reviews, they can
cast a wider net. And then you can re-encourage people
– researchers – to actually see that their results are
speaking to equity or inequity and that they publish those
results separate from other parts of the effectiveness re-
sults” (Interview # 13: policy/decision maker).
“Ethics matter”
The majority of the participants emphasized the need
for the explicit consideration of ethics within health
equity and randomized trials in the extension of the
CONSORT Statement. For example, participants
expressed concerns about inadvertently perpetuating in-
equity through the conduct and reporting of randomized
trials:
“This is probably a bit of my ethics background coming
in but you want to make sure that when you’re looking
at different things like race or gender – that you know
there’s a real purpose for it...that there’s a good fit with
your question and then I think that needs to be presented
in the background, but in a way that you know, people
reading it…would not view a certain group more
negatively because of that. You don’t want to contribute
to ongoing inequity” (Interview #6: researcher, ethicist).
Participants also described the need to consider con-
tributions to a broader social agenda about health
equity:
“They’re not thinking about what they can do with it so
they end up producing absolutely excellent and fantastic
RCTs [randomized controlled trials] over a large number
of years, it’s almost a careers work for some of them, and
they may not actually have even thought what, even in
the broadest terms, even when you say well what’s the
benefit to society? How is the human race going to benefit
from this?” (Interview #1: policy/decision maker, funder).
In addition, a few participants expressed concern
about standard ethical procedures as a barrier to inclu-
sive research conduct:
“…there’s an assumption that everybody is the same
and that things are appropriate for… the white middle
class population are going to be appropriate for other
communities without any idea that [factors such as]
culture, language need to be reflected in research if
they’re going to be relevant to the population. Consents
drive me crazy. You have a population where most
people can’t read or write and…give them a consent
form that is so word dense they look at it and assume
that they can’t understand it.”
“We’re all expected to use the evidence based methods
of treatment which is great except that the people we
work with would never in a million years have partici-
pated in any of the research” (Interview #4: policy/deci-
sion maker, participant/research collaborator)
“Describe unique research strategies”
All participants described how research methods could
themselves be used to promote equity – for example,
through new approaches to research and/or through bet-
ter reporting of the design and conduct of their research
that considers health equity:
“I think that even to remind people to think about…in
terms of developing methodologies or how things are go-
ing to be done…to think about it in terms of being
strengths based. Excluding people because they cannot
read or write or because they don’t have good memory or
because they’re not able to generate their own concepts. It
does not mean that they cannot participate and it
doesn’t mean that they don’t have important things to
offer. It just means that we have to get at that informa-
tion a little bit differently” (Interview # 4: policy/decision
maker, participant/research collaborator)
“Sometimes people do [consider equity issues in their
trial] but they don’t report it, they don’t even realize its
important” (Interview #12: editor)
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Many participants acknowledged that unique strategies
to consider health equity might be required, using trans-
parent and evidence-based approaches to science and in
a way that contributes to build knowledge about health
equity in research:
“So again, speaking largely from sex and gender, equity
overall has been, you know, not addressed or not ad-
dressed adequately. And...the other overall point and
maybe it applies to most is that randomized controlled
trials aren’t really designed to talk about context. It’s like
trials aren’t really designed to explicate enough about
equity, I think” (Interview # 10: researcher).
“[Researchers need to know] how to present short sim-
ple papers, and include equity focused results without
getting carried away, making it lengthy and dragging it
on”
(Interview #5: researcher, editor).
“Clarity of reporting”
All participants emphasized the importance of knowing
the details on who is – and who is not – included in the
study; that is, the participant and study context. They
also emphasized that it is important to include and re-
port clearly on populations that are not often included
in randomized trial designs (for example, Indigenous
people). Participants discussed the need for the CON-
SORT Statement to be extended to provide clarity of
reporting about study populations:
“Sometimes with the eligibility criteria I find that it
isn’t always reported clearly enough. When review au-
thors go to create a systematic review that’s one of the
main issues - that authors of trials haven’t reported fully
enough. They [authors of trials] do not give enough detail
and they [authors of systematic reviews] are not able to
decipher between male/female, sometimes even age”
(Interview #3: participant/ research collaborator).
Reporting research participant details using a social
determinants of health framework was recommended as
a helpful way to communicate differences in effect and
facilitate understandings of how individual characteris-
tics, such as gender, factor into differential effects of in-
terventions. It is also important to understand how
context (for instance, social, historical, political factors)
might impact the effects of the intervention:
“We often put…many of the characteristics that are in
PROGRESS Plus [a social determinants of health frame-
work] on our wish list to include them in our analyses
but we’re so limited - in terms of barriers – limited by
the data, there’s so much missing” (Interview #8:
researcher).
“For example, with the elderly, I’ve read different defi-
nitions, Some will say over 55 or 65, 75 - so if they [re-
searchers using reporting guidelines] could clarify the age
because depending on the definition there will be other,
more considerations as people age, of course there are
just more co-morbidities and different issues to consider”
(Interview #3: participant/research collaborator).
“Implications of equity for sampling and analysis”
Participants indicated the need for the extension of the
CONSORT Statement to accommodate statistics that
communicate important information about health equity
(i.e. they also emphasized the importance of reporting
on subgroup analyses to assess health inqualities). Many
participants indicated that it was important to encourage
researchers to report on features of their studies that re-
late to health equity and to use statistical methods to as-
sess diversity:
“So sample size is obviously important if you want to
know if equity is only coming into your study through
subgroup analysis [then] it’s important that you indicate
that you have enough sample – you know we often dis-
cuss sample size in terms of our overall study so we don’t
really talk about how, how well powered the study is for
subgroup analysis. I think sample size is somewhere it
could be particularly important to discuss equity”
(Interview # 5: researcher, editor).
“Because often you are looking for a more homogenous
group [in non-health equity trials]. If you’re looking for a
more diverse group then that might impact your sample
size. You probably need to put some consideration into
that when you report” (Interview #6: researcher, ethicist)
A few participants indicated that there is a need to re-
port on whether the subgroup analysis is pre-planned
and to ensure that these subgroup data are analyzed
appropriately:
“I guess for statistical methods…one would certainly
need to highlight what if any subgroup analysis will be
done and to state it a priori. The other thing is maybe
even a comment about missing [data] for the different
groups. Sort of being transparent about it as an issue for,
say, particular groups” (Interview #8: researcher).
“I think statistics are statistics and, you need to – you
might be looking at more subgrouping there but it’s just -
I don’t see any change [in the CONSORT Statement
checklist]” (Interview #13: policy/decision maker).
“Think beyond the immediate trial”
All participants discussed the importance of considering
the potential impacts of randomized trials. Participants
discussed the extension of the CONSORT Statement for
equity as having impacts on the future conduct and use
of research:
“I think that the details are very, very important and I
think that any rationale that a researcher has… for in-
cluding or excluding [study details] really gives good con-
textual information to the results. Because then it gives a
lot of information…people aren’t writing for today, they’re
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writing for 5 years from now” (Interview # 2: researcher,
participant/ research collaborator).
“People might read that and think that applicability –
is it applicable to my patient with stroke as opposed to,
you know, applicable to all patients with stroke living in
urban/rural, rich/poor, whatever the case might be”
(interview #11: researcher).
Some participants discussed the fact that greater
reporting of detail relative to health equity through the
CONSORT Statement would contribute to the synthesis
of randomized trials and also build evidence for inter-
ventions with impacts on health equity:
“An essential thing to report is how you have measured
this social factor for which you are now reporting differ-
ential results. I mean – measures of socioeconomic status
there are, of course, an almost infinite number of differ-
ent ways which one could do that and if you’re trying to
– in order to interpret – I would want to know in synthe-
sis how that had been determined” (Interview #7:
researcher).
“Everything, of course, should be explicit and as clear
as possible and then identify what was not done…there
are some wonderful studies, and then there’s sloppy stud-
ies. And, then when we get to the systematic review level
we see [that] some of the carelessness has ramifications”
(Interview # 10: researcher).
As well, some participants expressed concern about
potential intervention harms (including the exacerbation
of inequity) and the importance of reporting this:
“They might actually be perpetuating inequity that we
see in clinical practice because we simply don’t have
enough information on the effect of certain interventions
across different groupings” (Interview #2: researcher, par-
ticipant/research collaborator).
“I do trials with [devices] and it turns out that [these]
interventions can only be effectively applied with people
who already own [devices]. Because there is no way on a
pragmatic level you will distribute [devices] to everybody.
So by definition the intervention goes only for those who
already own [devices] and if there’s a benefit to that
intervention, as there often is, then you’re creating divide
between those who own [devices] and those who cannot
benefit from the interventions. So in some instances that
kind of intervention can be considered as creating an in-
equity and it would be a relevant unintended effect to be
reported” (Interview #9: reasearcher).
In summary, the key informant interviews were used
to elicit detailed perspectives from knowledge users on
ways to improve the reporting of intervention effects re-
lated to health equity in randomized trials. The key in-
formant interviews identified important concepts that
are not yet well articulated in the literature and that
were not generated in our other studies. The key inform-
ant interviews also allowed the expression of views and
sharing of knowledge by those who have direct experi-
ence in trials as participants, to expand thinking about
the implications of randomized trials in relation to
health equity. The interview findings were used to iden-
tify real-life issues and concerns and to stimulate discus-
sion about whether and how the CONSORT Statement
might be extended for equity in feasible ways.
Discussion
There were seven new themes identified that were not
previously found during other research activities under-
way to develop CONSORT-Equity 2017: “Differentiate
the type of trial”, “Prompts for health equity”, “Ethics
matter”, “Describe unique research strategies”, “Clarity
of reporting”, “Implications of equity for sampling and
analysis”, and “Think beyond the immediate trial”. These
themes and key informant data contributed to the
broader CONSORT- Equity 2017 research agenda. The
concepts identified in the key informant interviews were
subsequently affirmed during the international online
survey and in the face-to-face consensus meeting held to
debate extension of the CONSORT Statement for equity.
For example, the focus on ethics that was identified by
all key informant interviews led to the addition of a new
item on ethical concerns in CONSORT-Equity 2017.
Furthermore, 16 items were identified for a health equity
extension from key informant interviews (Table 4). The
key informant interviews prompted the inclusion of
these new concepts about health equity in relation to
randomized trials, and the value-added by the key in-
formant interviews to CONSORT-Equity 2017 affirmed
the use of an integrated knowledge translation approach
in guideline development.
The key informant interviews were conducted with
those for whom CONSORT-Equity 2017 might be rele-
vant and are an example of integrated knowledge trans-
lation (KT). The approach used in this qualitative study
is congruent with and complementary to the broader in-
tegrated KT research approach used in the series of
studies to develop CONSORT-Equity 2017 and in which
knowledge users had been partners in the design, con-
duct, analysis, and reporting of the research studies. In-
tegrated KT is an approach to research that involves
engaging knowledge users (those who can act on re-
search findings) in the research process – from defining
the research question to the application of findings [14].
This approach to research is undertaken with the ex-
pectation that the outputs of the research will be rele-
vant, useful, and useable; that is, more likely to be
applied in practice and policy and, create greater cap-
acity to use research by knowledge users [12, 21].
Participants who identified as participant/community
collaborators provided new insights and clarity on what
matters to patients and the public, in relation to health
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equity and randomized trials: concerns about the use of
standard ethical procedures as a barrier to inclusive re-
search conduct (see theme “Ethics matter”), how re-
search methods could themselves be used to promote
equity with new approaches to research (see theme “De-
scribe unique research strategies”), a need to include and
report clearly on populations that are not often included
in randomized trials (see theme “ Clarity of reporting”),
and to consider the longer-term impacts of the CON-
SORT Equity 2017 extension for future conduct and use
of research (see theme “Think beyond the immediate
trial”). These contributions introduced ideas and per-
spectives (forms of knowledge) that had not originally
been anticipated in our study and that led to insights
and discussion in subsequent stages of the larger research
study and eventually changes in the reporting guideline
(see Table 4). The use of semi-structured interviews pro-
vided the opportunity for knowledge user participants, in-
cluding patients - a group not before included in
reporting guideline development – to work with peers in
research systems and to include their views. Our study is
an example of a way that forms of knowledge from patient
groups can be incorporated in such research, giving them
the opportunity to engage in the development of data that
incorporated their views directly into the work done to
develop CONSORT-Equity 2017. The approach to engage
knowledge users as partners throughout the process was a
way to foster thinking and action for the inclusion of per-
spectives that included key informants in a previously
established process of guideline development.
Our work promotes a structured and evaluative ap-
proach to the use of key informant interviews in guide-
line development. In a review of all other existing and
proposed CONSORT Statement extensions we found
that a similar approach was only used in one extension
(CONSORT Statement extension for herbal interven-
tions). In this extension, telephone interviews were con-
ducted as part of a three-stage guideline development
process, in which there was pre-meeting item generation
and suggestions for revisions to the existing CONSORT
Statement in preparation for the consensus meeting and
then post-meeting feedback. However, the conduct of a
qualitative study was not reported therein [22].
In our study, the key informant interviews facilitated
collaborative engagement and involvement with know-
ledge users, and created opportunities for different
knowledges to coexist within an established and aca-
demic approach to guideline development. Approaches
to the engagement of participants/community collabora-
tors in randomized trials and in particular the develop-
ment of reporting guidelines are not yet well established,
and this study can provide an example. It is important
that a culture of inclusion is fostered in the reporting of
research: we encourage those in research systems as well
as knowledge users themselves to recognize the value
and feasibility of knowledge user inclusion that includes
patients.
Our process of guideline development used an inte-
grated KT approach, affirms knowledge user engagement
in the established guideline development process [22]
and is expanded to include knowledge users who are
also patient consumers (participants/research collabora-
tors) of the evidence reported by CONSORT-Equity
2017. The key informant interviews were an integral fea-
ture of the guideline development process, and served to
identify the real-life application of equity-related con-
cepts generated within the context of randomized trials.
Limitations and Strengths
One limitation of this study is that we engaged with a
small and diverse group of key informants with 3 of the
13 identifying as participant/community collaborators
(people who are patients and who are active in research),
and the remainder consisting of a funder, ethicist, re-
searchers, publisher/journal editors, and policy maker.
As well, the sample of participants was biased in favour
of researchers as users of the CONSORT Statement ra-
ther than community members or members who identi-
fied as part of a group that experiences disadvantage
within health systems, a reflection of a broader research
environment in which there is extremely limited report-
ing of patient engagement and involvement in random-
ized trials [23]. In addition, the study used qualitative
methods that are not well established in guideline devel-
opment (that is, the use of key informant interviews).
This study had several strengths. For example, the key
informant study (from design through to the conduct
and interpretation) involved an international and
inter-disciplinary study executive and advisory board
and so reflected a broad array of views that includes
members who identify as part of a group that experi-
ences disadvantage within health systems as well as
members of other knowledge user groups (funders, edi-
tors, ethicists et cetera). While there was an in-depth
focus on those who are known users of CONSORT
Statement as a reporting guideline, we expanded the def-
inition of knowledge user to include those who are also
consumers (research participants who are patients, com-
munity members who choose to collaborate in research)
of the evidence reported by CONSORT-Equity 2017.
This meant that there was purposeful recruitment of re-
search participants/community collaborators to ensure
consideration and incorporation of their views. We were
striving to introduce participation of patients in an area
for which there is limited guidance and reported involve-
ment and sought additional participant/community col-
laborators without success. However, the participant/
community collaborators we did engage made substantial
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contributions to the study and demonstrated to all that
participant/community collaborators can play a valued
role, and in a way that is feasible to incorporate into estab-
lished guideline development processes. As there is ‘road-
testing’ of the CONSORT-Equity 2017 planned as part of
the guideline dissemination [11] there are further oppor-
tunities for involvement and engagement that leads to
feedback on CONSORT-Equity 2017 by knowledge users.
Our use of key informant interviews was used to integrate
real-world experience in health systems and contributes to
the development of knowledge about a research guideline
and demonstrates that there is an important role for
knowledge users that include patients in the guideline de-
velopment process.
Another strength is that the approach used in the key
informant interviews accommodated the socio-cultural
context of those participating in the interviews and
maintained the fidelity of the CONSORT Statement.
Two researchers were involved in the data coding and
thematic development and there was member-checking
of interviews for accuracy. The study executive members
who were involved in the study had previous experience
with the extension of other statements [24].
Finally, a consensus meeting attended by a broad range
of potential knowledge users from high, middle and low
income countries, including patients and methodologists
[11, 25], affirmed the relevance of the key informant
themes to the development of the CONSORT-Equity
2017 as a reporting guideline.
Conclusion
The CONSORT-Equity 2017 statement promotes the
reporting of factors that relate to unfair and avoidable
differences between population groups. To help extend
the CONSORT Statement for equity, we interviewed key
informants who are potential CONSORT-Equity 2017
users to elicit knowledge user perspectives on the ways
to improve reporting of intervention effects related to
health equity in randomized trials. We used key inform-
ant interviews to obtain a detailed assessment of know-
ledge user perspectives and to identify ways to improve
reporting of intervention effects related to health equity
in randomized trials. We have described the findings
from the key informant interviews on items for reporting
to assess the effects of an intervention on health equity,
and how the findings from key informant inteviews were
used to develop a reporting guideline. We encourage the
use of key informant interviews to engage and involve
all knowledge users, including patients, to ensure the in-
clusion of real-life expertise in guideline development.
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